Dyne Therapeutics, Inc. · NASDAQ:DYN

Rhodes Jason P sold 834,302 Dyne Therapeutics, Inc. shares (Form 4)

Traded Apr 20 to Apr 22, 2026 · Filed Apr 22, 2026

From Apr 20 to Apr 22, 2026, Rhodes Jason P (Director) sold 834,302 Dyne Therapeutics, Inc. shares at an average US$19.75 for US$16.5M under a trading plan, leaving 1,285,704 shares. Filed Apr 22, 2026 (Form 4).

Sold
834,302 shares
Price
US$19.75 average (US$19.51 to US$20.06)
Value
US$16.5M
Holding after
1,285,704 shares (held indirectly)
Trading plan
Yes (Made under a plan set in advance)
Role
Director

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Apr 20, 2026Common StockSale71,676US$20.061,886,751Indirect
Apr 20, 2026Common StockSale142,604US$20.065,554,904Indirect
Apr 20, 2026Common StockSale1,401US$20.0614,561Indirect
Apr 20, 2026Common StockSale56,368US$20.061,402,200Indirect
Apr 21, 2026Common StockSale71,499US$19.511,815,252Indirect
Apr 21, 2026Common StockSale142,253US$19.515,412,651Indirect
Apr 21, 2026Common StockSale1,398US$19.5113,163Indirect
Apr 21, 2026Common StockSale56,228US$19.511,345,972Indirect
Apr 21, 2026Common StockSale769US$20.051,814,483Indirect
Apr 21, 2026Common StockSale1,530US$20.055,411,121Indirect
Apr 21, 2026Common StockSale15US$20.0513,148Indirect
Apr 21, 2026Common StockSale605US$20.051,345,367Indirect
Apr 22, 2026Common StockSale75,866US$19.681,738,617Indirect
Apr 22, 2026Common StockSale150,942US$19.685,260,179Indirect
Apr 22, 2026Common StockSale1,485US$19.6811,663Indirect
Apr 22, 2026Common StockSale59,663US$19.681,285,704Indirect

Source

View original at SEC

Related